Understand the source comparison
PE-22-28 Legal Comparison: Research Peptides vs FDA-Approved Drugs vs Controlled Substances
Understanding where PE-22-28 sits in the regulatory landscape requires comparing it to other substance categories. Research Peptides (PE-22-28, BPC-157, Thymosin Alpha-1) FDA under FDCA Unapproved drugs; legal for research use only In vitro studies, animal res
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding where PE-22-28 sits in the regulatory landscape requires comparing it to other substance categories.
- Research Peptides (PE-22-28, BPC-157, Thymosin Alpha-1)
- FDA under FDCA
- Unapproved drugs; legal for research use only
- In vitro studies, animal research, laboratory investigation
- Moderate—targets suppliers making health claims
- Compliant when sold by registered suppliers with research-only labeling; high enforcement risk if marketed for human use
- FDA-Approved Peptide Drugs (Semaglutide, Insulin, Oxytocin)
- Approved drugs; prescription required
- Human therapeutic use under prescriber supervision
- High—targets counterfeit or diverted product
- Legal for patient use only with valid prescription; requires pharmacy dispensing
- Compounded Peptides (Tirzepatide from 503B facilities)
- FDA under FDCA + state boards
- Legal when compounded under 503B; not FDA-approved as finished product
- Patient-specific prescriptions during drug shortages
- Moderate—targets facilities exceeding scope
- Legally distinct from research peptides; requires prescriber oversight
- Controlled Substances (Schedule I-V)
- DEA under Controlled Substances Act
- Scheduled drugs; possession without prescription is criminal
- Varies by schedule; medical use for II-V, none for I
- Highest—criminal enforcement
- PE-22-28 is not a controlled substance; possession for research is not a DEA violation
- Dietary Supplements
- FDA under DSHEA
- Lawful if no drug claims made; no pre-market approval required
- Consumer use without prescription
- Low unless adultered or mislabeled
- PE-22-28 cannot legally be sold as a supplement; doing so violates FDCA
- PE-22-28 legal status is closest to the research peptide category—lawful when sold for laboratory use, prohibited when marketed for human therapeutic application. It is not a controlled substance, which means possession alone does not trigger DEA enforcement. However, selling it as a dietary supplement or making health claims converts it into an unapproved drug subject to FDA seizure and warning letters.